Clinical significance of cancer/testis antigens expression in patients with non-small cell lung cancer
Clinical significance of cancer/testis antigens expression in patients with non-small cell lung cancer
复制标题
DOI：
10.1016/j.lungcan.2009.05.010
复制
发表时间：
2010-04-01
期刊：
影响因子：
5.3
通讯作者：
Yasumoto, Kosei
中科院分区：
文献类型：
--
作者：
Shigematsu, Yoshiki;Hanagiri, Takeshi;Yasumoto, Kosei
癌症/睾丸抗原（CT抗原）被认为是抗原特异性免疫治疗的合适靶点，因为在各种正常组织中除睾丸外都有癌症特异性表达，而FILA I类在睾丸中不表达。在本研究中，通过RT-PCR分析了非小细胞肺癌（NSCLC）中CT抗原（MAGE-A3、MAGE-A4、NY-ESO-1和KK-LC-1）的表达。研究对象为2001年至2005年在我科接受手术的239例NSCLC患者。 NSCLC患者中MAGE-A3、MAGE-A4、NY-ESO-1和KK-LC-1的表达率分别为23.8%、20.1%、10.5%和32.6%。 MAGE-A4 在男性 (25.3%) 中的表达频率高于女性 (10.6%) (p < 0.01)。 MAGE-A4 的阳性比例在 II-IV 期 (30.6%) 高于 1 期 (12.8%) (p < 0.01)。 MAGE-A3 和 MAGE-A4 在鳞状细胞癌中的表达频率高于在腺癌中的表达 (p < 0.01)。在NY-ESO-1和KK-LC-1表达中没有观察到这种趋势。 KK-LC-1 在 32.1% 的腺癌患者和 36.5% 的鳞状细胞癌患者中表达。 MAGE-A4 表达阳性的患者的总体生存率明显低于 MAGE-A4 表达不表达的患者 (p = 0.013)，并且当分析仅限于 I 期患者时，也观察到了这种对生存的影响 (p = 0.0037)。 MAGE-A3、NY-ESO-1 或 KK-LC-1 的表达不会显着影响 NSCLC 患者的生存，然而，至少一种此类 CT 抗原的表达会对 NSCLC 患者的生存产生负面影响 (p = 0.045)。 (C) 2009 Elsevier Ireland Ltd. 保留所有权利。
Cancer/testis antigens (CT antigens) are thought to be suitable targets for antigen-specific immunotherapy, because of the cancer-specific expression except for the testis among various normal tissues and no-expression of FILA class I in the testis. In the present study, the expressions of CT antigens (MAGE-A3, MAGE-A4, NY-ESO-1 and KK-LC-1) in non-small cell lung cancer (NSCLC) were analyzed by RT-PCR. The subjects were 239 patients with NSCLC who underwent surgery from 2001 to 2005 in our department. The expression rates of MAGE-A3, MAGE-A4, NY-ESO-1 and KK-LC-1 were 23.8%, 20.1%, 10.5% and 32.6% in patients with NSCLC, respectively. MAGE-A4 was expressed more frequently in male (25.3%) than in female (10.6%) (p < 0.01). The positive proportion of MAGE-A4 was higher in stages II-IV (30.6%) than in stage 1(12.8%) (p < 0.01). Both of MAGE-A3 and MAGE-A4 were expressed more frequently in squamous cell carcinoma than in adenocarcinoma (p < 0.01). Such tendency was not observed among NY-ESO-1 and KK-LC-1 expression. KK-LC-1 was expressed in 32.1% of patients with adenocarcinoma and in 36.5% of patients with squamous cell carcinoma. Patients with positive MAGE-A4 expression showed significantly poorer overall survival than those without MAGE-A4 expression (p = 0.013), and such effect on survival was also observed, when the analysis was limited to patients at stage I (p = 0.0037). Expression of MAGE-A3, NY-ESO-1 or KK-LC-1 did not affect survival of patients with NSCLC significantly, however, expression of at least one of such CT antigens negatively affect survival of patients with NSCLC (p = 0.045). (C) 2009 Elsevier Ireland Ltd. All rights reserved.